IL142910A0 - Combination therapy to treat hepatitis b virus - Google Patents

Combination therapy to treat hepatitis b virus

Info

Publication number: IL142910A0
Authority: IL; Israel
Prior art keywords: virus; combination; alternation; administering; directed
Prior art date: 1998-11-02

Application number

IL14291099A

Other languages

English (en)

Original Assignee

Triangle Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-02

Filing date

1999-11-02

Publication date

2002-04-21

1999-11-02 Application filed by Triangle Pharmaceuticals Inc filed Critical Triangle Pharmaceuticals Inc

2002-04-21 Publication of IL142910A0 publication Critical patent/IL142910A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Plural Heterocyclic Compounds (AREA)

IL14291099A 1998-11-02 1999-11-02 Combination therapy to treat hepatitis b virus IL142910A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10666498P	1998-11-02	1998-11-02
PCT/US1999/025673 WO2000025797A1 (en)	1998-11-02	1999-11-02	Combination therapy to treat hepatitis b virus

Publications (1)

Publication Number	Publication Date
IL142910A0 true IL142910A0 (en)	2002-04-21

Family

ID=22312611

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL14291099A IL142910A0 (en)	1998-11-02	1999-11-02	Combination therapy to treat hepatitis b virus
IL142910A IL142910A (en)	1998-11-02	2001-05-01	Use of combinations of agents for the preparation of medicaments for treatment of hepatitis b virus
IL193148A IL193148A (en)	1998-11-02	2008-07-31	Medicine combined with hepatitis B virus

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL142910A IL142910A (en)	1998-11-02	2001-05-01	Use of combinations of agents for the preparation of medicaments for treatment of hepatitis b virus
IL193148A IL193148A (en)	1998-11-02	2008-07-31	Medicine combined with hepatitis B virus

Country Status (16)

Country	Link
US (3)	US6528515B1 (xx)
EP (3)	EP1380303B1 (xx)
JP (2)	JP2002528508A (xx)
KR (1)	KR100632520B1 (xx)
CN (3)	CN1891221A (xx)
AT (3)	ATE457734T1 (xx)
AU (1)	AU1810600A (xx)
CY (2)	CY1108635T1 (xx)
DE (3)	DE69942042D1 (xx)
DK (2)	DK1380303T3 (xx)
ES (3)	ES2338642T3 (xx)
HK (1)	HK1062146A1 (xx)
ID (1)	ID29471A (xx)
IL (3)	IL142910A0 (xx)
PT (2)	PT1382343E (xx)
WO (1)	WO2000025797A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1380303B1 (en) *	1998-11-02	2008-09-17	Gilead Sciences, Inc.	Combination therapy to treat hepatitis B virus
JP4863619B2 (ja) *	2002-06-19	2012-01-25	フィドゥリン	ストレス、不安及び攻撃性を緩和する鳥類宥和フェロモン
AU2003253888A1 (en) *	2002-07-15	2004-02-02	Gilead Sciences, Inc.	Combination therapies with l-fmau for the treatment of hepatitis b virus infection
ATE398455T1 (de) *	2003-01-14	2008-07-15	Gilead Sciences Inc	Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
KR20100127180A (ko) *	2009-05-25	2010-12-03	부광약품 주식회사	클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
WO2011145808A2 (ko) *	2010-05-18	2011-11-24	부광약품 주식회사	클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
CA2819548C (en)	2010-12-10	2019-04-09	Sigmapharm Laboratories, Llc	Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
JP6779232B2 (ja) *	2015-05-08	2020-11-04	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体
CN105943547B (zh) *	2016-05-23	2018-01-19	北京慧宝源生物技术股份有限公司	抗hbv的药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5684153A (en)	1984-08-16	1997-11-04	Beecham Group Plc	Process for the preparation of purine derivatives
EP0141927B1 (en) *	1983-08-18	1991-10-30	Beecham Group Plc	Antiviral guanine derivatives
US5223263A (en)	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
CS264222B1 (en)	1986-07-18	1989-06-13	Holy Antonin	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
WO1989002733A1 (en)	1987-09-22	1989-04-06	The Regents Of The University Of California	Liposomal nucleoside analogues for treating aids
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8904855D0 (en) *	1989-03-03	1989-04-12	Beecham Group Plc	Pharmaceutical treatment
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en)	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en)	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5700937A (en)	1990-02-01	1997-12-23	Emory University	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6069252A (en)	1990-02-01	2000-05-30	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en)	1990-02-01	2003-11-04	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
AU7872491A (en)	1990-05-07	1991-11-27	Vical, Inc.	Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en)	1990-05-29	1991-12-12	Vical, Inc.	Synthesis of glycerol di- and triphosphate derivatives
CA2083386C (en)	1990-06-13	1999-02-16	Arnold Glazier	Phosphorous prodrugs
US5674869A (en) *	1990-07-07	1997-10-07	Beecham Group Plc	Pharmaceutical treatment
US5674849A (en)	1990-10-24	1997-10-07	Allelix Biopharmaceuticals Inc.	Anti-viral compositions
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5149794A (en)	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
US5543389A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en)	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5444063A (en)	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en)	1990-12-05	1993-01-12	University Of Georgia Research Foundation, Inc.	Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5925643A (en)	1990-12-05	1999-07-20	Emory University	Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en)	1991-01-03	1995-12-08	Iaf Biochem Int	PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en)	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
GB9110874D0 (en)	1991-05-20	1991-07-10	Iaf Biochem Int	Medicaments
CA2112803A1 (en)	1991-07-12	1993-01-21	Karl Y. Hostetler	Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en)	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en)	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues
US6177435B1 (en)	1992-05-13	2001-01-23	Glaxo Wellcome Inc.	Therapeutic combinations
JPH08510236A (ja)	1993-05-12	1996-10-29	カールワイ．ホステトラー	局所使用のためのアシクロビル誘導体
US5587362A (en)	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
US5696277A (en)	1994-11-15	1997-12-09	Karl Y. Hostetler	Antiviral prodrugs
US5703058A (en) *	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en)	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en)	1995-03-16	1999-02-09	Yale University	Reducing toxicity of L-nucleosides with D-nucleosides
WO1998023285A1 (en) *	1996-11-29	1998-06-04	Smithkline Beecham Plc	Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
WO1998041522A1 (en) *	1997-03-19	1998-09-24	Emory University	Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
EP1380303B1 (en) *	1998-11-02	2008-09-17	Gilead Sciences, Inc.	Combination therapy to treat hepatitis B virus

1999
- 1999-11-02 EP EP03077542A patent/EP1380303B1/en not_active Expired - Lifetime
- 1999-11-02 ID IDW00200101179A patent/ID29471A/id unknown
- 1999-11-02 PT PT03077543T patent/PT1382343E/pt unknown
- 1999-11-02 AT AT03077543T patent/ATE457734T1/de active
- 1999-11-02 EP EP03077543A patent/EP1382343B1/en not_active Expired - Lifetime
- 1999-11-02 JP JP2000579237A patent/JP2002528508A/ja not_active Ceased
- 1999-11-02 DK DK03077542T patent/DK1380303T3/da active
- 1999-11-02 ES ES03077543T patent/ES2338642T3/es not_active Expired - Lifetime
- 1999-11-02 PT PT03077542T patent/PT1380303E/pt unknown
- 1999-11-02 WO PCT/US1999/025673 patent/WO2000025797A1/en active Application Filing
- 1999-11-02 IL IL14291099A patent/IL142910A0/xx unknown
- 1999-11-02 DE DE69942042T patent/DE69942042D1/de not_active Expired - Lifetime
- 1999-11-02 EP EP99961553A patent/EP1124562B1/en not_active Expired - Lifetime
- 1999-11-02 CN CNA2006100999317A patent/CN1891221A/zh active Pending
- 1999-11-02 AT AT99961553T patent/ATE287268T1/de not_active IP Right Cessation
- 1999-11-02 DE DE69939604T patent/DE69939604D1/de not_active Expired - Lifetime
- 1999-11-02 DK DK03077543.1T patent/DK1382343T3/da active
- 1999-11-02 ES ES99961553T patent/ES2237189T3/es not_active Expired - Lifetime
- 1999-11-02 ES ES03077542T patent/ES2314157T3/es not_active Expired - Lifetime
- 1999-11-02 AU AU18106/00A patent/AU1810600A/en not_active Abandoned
- 1999-11-02 CN CNB99814147XA patent/CN1173705C/zh not_active Expired - Fee Related
- 1999-11-02 KR KR1020017005515A patent/KR100632520B1/ko not_active IP Right Cessation
- 1999-11-02 US US09/432,247 patent/US6528515B1/en not_active Expired - Lifetime
- 1999-11-02 CN CNA2004100771301A patent/CN1666742A/zh active Pending
- 1999-11-02 AT AT03077542T patent/ATE408410T1/de active
- 1999-11-02 DE DE69923338T patent/DE69923338T2/de not_active Expired - Lifetime
2001
- 2001-05-01 IL IL142910A patent/IL142910A/en not_active IP Right Cessation
2003
- 2003-02-25 US US10/374,363 patent/US7572800B2/en not_active Expired - Fee Related
2004
- 2004-07-14 HK HK04105176.1A patent/HK1062146A1/xx not_active IP Right Cessation
2008
- 2008-07-31 IL IL193148A patent/IL193148A/en not_active IP Right Cessation
- 2008-12-10 CY CY20081101433T patent/CY1108635T1/el unknown
2009
- 2009-06-12 US US12/483,800 patent/US20090247487A1/en not_active Abandoned
2010
- 2010-04-30 CY CY20101100385T patent/CY1110629T1/el unknown
- 2010-11-11 JP JP2010252915A patent/JP2011079840A/ja active Pending

Also Published As

Publication number	Publication date
ATE457734T1 (de)	2010-03-15
ATE408410T1 (de)	2008-10-15
CY1108635T1 (el)	2014-04-09
DE69939604D1 (de)	2008-10-30
CN1891221A (zh)	2007-01-10
IL193148A0 (en)	2009-02-11
ES2314157T3 (es)	2009-03-16
DK1382343T3 (da)	2010-04-26
EP1380303B1 (en)	2008-09-17
US20030158150A1 (en)	2003-08-21
CN1329497A (zh)	2002-01-02
EP1382343B1 (en)	2010-02-17
ES2237189T3 (es)	2005-07-16
AU1810600A (en)	2000-05-22
DE69923338D1 (de)	2005-02-24
US7572800B2 (en)	2009-08-11
HK1062146A1 (en)	2004-10-21
WO2000025797A1 (en)	2000-05-11
EP1380303A1 (en)	2004-01-14
ID29471A (id)	2001-08-30
IL142910A (en)	2009-06-15
ATE287268T1 (de)	2005-02-15
JP2011079840A (ja)	2011-04-21
ES2338642T3 (es)	2010-05-11
CN1173705C (zh)	2004-11-03
PT1380303E (pt)	2008-11-03
DE69923338T2 (de)	2006-04-06
CN1666742A (zh)	2005-09-14
PT1382343E (pt)	2010-03-10
US20090247487A1 (en)	2009-10-01
JP2002528508A (ja)	2002-09-03
IL193148A (en)	2011-09-27
EP1382343A1 (en)	2004-01-21
EP1124562B1 (en)	2005-01-19
KR20010082282A (ko)	2001-08-29
CY1110629T1 (el)	2015-04-29
KR100632520B1 (ko)	2006-10-09
US6528515B1 (en)	2003-03-04
DK1380303T3 (da)	2008-12-01
DE69942042D1 (de)	2010-04-01
EP1124562A1 (en)	2001-08-22

Publication	Publication Date	Title
IL193148A0 (en)	2009-02-11	Use of combinations of agents for the preparation of medicaments for treatment of hepatitis b virus
PL296460A1 (en)	1993-12-13	Method of obtaining a trombine preparation effectively protected against viruses
YU92102A (sh)	2006-01-16	Metode i smeše za lečenje virusnog hepatitisa c
HU912359D0 (en)	1991-12-30	The use of flupirtine active agents for treating muscle-tension
ATE207355T1 (de)	2001-11-15	Behandlung von hyperproliferativen gefässerkrankungen
GR1002767B (el)	1997-09-17	Αντιπαρασιτικη συνθεση για την θεραπεια και την προστασια των ζωων συντροφιας.
BR9808221A (pt)	2000-05-16	Método de tratamento de tumor.
IL151981A0 (en)	2003-04-10	Method of treating hepatitis delta viral infection
ATE150317T1 (de)	1997-04-15	Synergische mischung zur behandlung von herpes
ATE281173T1 (de)	2004-11-15	Behandlung einer virusinfektion bei schweinen
ATE178336T1 (de)	1999-04-15	Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
ATE255417T1 (de)	2003-12-15	Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE72115T1 (de)	1992-02-15	Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
PH27309A (en)	1993-05-28	Prevention of glycoprotein enveloped virus infectivity by quinolyl-and isoquinolyloxazone-2-ones